Recent News

• 09.16.2025 - BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
• 08.21.2025 - BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
• 08.20.2025 - BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
• 08.13.2025 - BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
• 07.30.2025 - BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
• 07.30.2025 - BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025

Recent Filings

• 09.16.2025 - EX-99.1 EX-99.1
• 09.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.21.2025 - EX-99.1 EX-99.1
• 08.20.2025 - EX-99.1 EX-99.1
• 08.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2025 - EX-99.1 EX-99.1